Status:
COMPLETED
A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The combination of docetaxel and gemcitabine has shown significant activity in patients with metastatic breast cancer. Several studies have activity in patients of multiple lines of therapy, including...
Eligibility Criteria
Inclusion
- Advanced or metastatic breast cancer
- Disease that can be measured by the physician or radiologic test.
- May have had one chemotherapy treatment for advanced or metastatic disease.
- Patients may have received any prior adjuvant chemotherapy, including taxane containing regimens, provided this treatment was completed at least 6 months prior to enrollment.
- Patients may have received prior hormone therapy or immunotherapy.
Exclusion
- Patients with only non-measurable disease
- Cancer that has spread to the brain
- A patient who received a taxane with metastatic disease.
- Pregnancy
- Patients who received prior gemcitabine
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00191672
Start Date
December 1 2003
End Date
November 1 2006
Last Update
January 26 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nashville, Tennessee, United States
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Katy, Texas, United States